RBC Capital Rates uniQure (QURE) buy, $65 Price Target
RBC Capital has reaffirmed its buy rating on uniQure N.V. with a new price target of $65.00, a 36.15% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
RBC Capital rated uniQure N.V. ($QURE) "buy" with a $65 price target on June 18, 2026.
Since the rating, $QURE is up 6.1% after 1 week, down 14.2% after 1 month and down 53.0% to date (from the $46.29 close on Jun 18, 2026).
QURE
uniQure N.V.
Key Points
- On June 18, 2026, RBC Capital reiterated its buy rating on uniQure N.V. with a price target of $65.00, up from a prior target of $48.00.
- RBC Capital's $65 price target implies 36.15% upside from uniQure N.V.'s ($QURE) current $47.74 share price.
- uniQure's stock is currently trading at $47.74, showing significant potential for growth given its new target price.
- Analysts have a consensus recommendation of strong buy with a mean target price of $61.46, reflecting positive expectations for the company's future.
Get $QURE trade alerts by text
We text you when insiders, Congress or big funds trade $QURE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures
RBC Capital Reiterates Buy Rating
On June 18, 2026, RBC Capital reiterated its buy rating on uniQure N.V. (NasdaqGS: QURE) with a price target of $65.00, increased from a previous target of $48.00. The stock is currently trading at $47.74, indicating a potential upside.
What Changed in RBC Capital's View
RBC Capital's updated target reflects a positive outlook for uniQure. The firm sees value in the company's innovative gene therapy treatments, especially as it moves forward with its product candidates. The new target suggests a significant upside from the current trading price.
Analysts Set New Price Targets
RBC Capital's recent action follows a series of mixed ratings from other analysts. On October 5, 2026, Barclays downgraded its rating on uniQure to Equal-Weight with a target of $28.00, down from $60.00. Conversely, on July 30, 2026, Wells Fargo maintained an Overweight rating with a target of $75.00, while Goldman Sachs also maintained a Neutral rating with a target of $31.00 as of September 30, 2026. Overall, the consensus among analysts remains a strong buy with a mean target price of $61.46.
How uniQure N.V. Stock Has Traded
uniQure's stock has shown a strong performance this year, currently trading at $47.74, which is significantly higher than its 52-week low of $8.73. This price action indicates a recovery, especially as the stock had previously reached a high of $71.50. The stock trades well above its 50-day moving average of $40.20, suggesting positive momentum.
$QURE price target
uniQure N.V. daily closes and this analyst's $65 target. Not advice.
Recent Earnings
In its most recent earnings report, uniQure reported revenue of $18.67 million, showing a growth rate of 11%. The company is still in the development phase for many of its products, including AMT-130 for Huntington's disease and AMT-260 for epilepsy. The next earnings report is scheduled for November 9, 2026.
What uniQure N.V. Does
uniQure N.V. specializes in developing gene therapies for patients with rare diseases. Its lead product, HEMGENIX, helps patients with hemophilia B. The company is actively working on several clinical trials for various conditions, showcasing its commitment to innovative healthcare solutions.
What to Watch at uniQure N.V.
Investors will be keeping an eye on uniQure's upcoming earnings report on November 9, 2026, as well as any further updates from analysts regarding the company's performance. As a reminder, RBC Capital's rating reflects its confidence in uniQure's growth potential, which may not represent the firm's current position.
Related Filing Alerts
Source: RBC Capital's rating change on $QURE (Jun 18, 2026). Written by software, not financial advice. How we make alerts